Tranexamsaeure en es it fr

Tranexamsaeure Brand names, Tranexamsaeure Analogs

Tranexamsaeure Brand Names Mixture

  • No information avaliable

Tranexamsaeure Chemical_Formula


Tranexamsaeure RX_link

Tranexamsaeure fda sheet

Tranexamsaeure FDA

Tranexamsaeure msds (material safety sheet)

Tranexamsaeure MSDS

Tranexamsaeure Synthesis Reference

No information avaliable

Tranexamsaeure Molecular Weight

388.458 g/mol

Tranexamsaeure Melting Point

188.7 oC

Tranexamsaeure H2O Solubility

40 mg/L

Tranexamsaeure State


Tranexamsaeure LogP


Tranexamsaeure Dosage Forms

Capsules (300 mg) for oral administration; Suppositories (200 mg); Injectable (100 mg, 200 mg)

Tranexamsaeure Indication

For the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

Tranexamsaeure Pharmacology

Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.

Tranexamsaeure Absorption

The relative bioavailability of the capsule formulation compared to the solution is 100%.

Tranexamsaeure side effects and Toxicity

Oral LD50 in mice is 1600 mg/kg.

Tranexamsaeure Patient Information

No information avaliable

Tranexamsaeure Organisms Affected

Humans and other mammals